Vincentage Pharma reported that its once-daily oral small-molecule GLP-1 receptor agonist VCT-220 met primary endpoints in a pivotal Phase 3 trial in overweight or obese patients in China. The company plans to submit an NDA to China’s National Medical Products Administration for chronic weight management. In the 52-week data set, VCT-220 produced mean body-weight reductions of -12.2% (120 mg) and -12.4% (160 mg), versus -1.3% for placebo, supporting the trial’s comparative efficacy design. The outcome strengthens the case for oral peptide-mimetic GLP-1 pharmacology as a competitive alternative to injectable GLP-1 therapies.